1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Baseline descriptives and MR imaging characteristics
Characteristics Dataset A (n = 169) Dataset B, Placebo (n = 69) Patient Female/male 123:46 50:19 RRMS/SPMS with relapses 169:0 57:12 Mean age (SD) 35.4 (8.4) 38.5 (9.1) Mean disease duration in years (SD) 6.4 (5.3) 5.9 (5.9) Median baseline EDSS (IQR) 2.0 (1.5–3.5) 2.5 (1.5–3.5) MR imaging % Inactive patients 41.4% 69.6% Mean number of enhancing lesions (SD) 2.4 (4.1) 1.3 (0.4)
Note:—EDSS indicates Expanded Disability Status Scale; IQR, interquartile range.